Across TCGA pan-cancer cohorts, FAM169A Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FAM169A data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher FAM169A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM169A expression acts as an unfavorable survival marker.

OV, LUSC, and COAD are the cancer types where FAM169A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.214	0.541	.023	18	view →
LUSC	DFS	Median	III,IV	0.212	0.553	.040	6	view →
COAD	OS	Median	All	0.500	0.871	.013	6	view →
SKCM	OS	Median	All	0.456	0.783	.044	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: FAM169A tumor-vs-normal RNA expression · all FAM169A data types